Traduction de « 14 lc which benefited from » (Néerlandais → Français) :

Recently launched products provided important contributions in Oncology (USD 2.5 billion, +14% lc), which benefited from the new anti-cancer medicine Afinitor (USD 32 million) approved in 2009 and new clinical data supporting Tasigna (USD 68 million, +101% lc).
Oncologie (USD 2,5 milliards, +14% en m. l) a profité d’importantes contributions des nouveaux produits, en particulier Afinitor (USD 32 millions), médicament anticancer homologué en 2009, et de nouveaux résultats cliniques supportant Tasigna (USD 68 millions, +101% en m. l.).

Neuroscience and Ophthalmics (USD 1.0 billion, +14% lc) benefited from dynamic growth in Lucentis (USD 228 million, +60% lc) and the Exelon franchise (USD 209 million, +33% lc) following the launch of the new Exelon Patch skin patch formulation in 2007.
Neurosciences et Ophtalmologie (USD 1,0 milliard, +14% en m. l) ont bénéficié du dynamisme de la croissance de Lucentis (USD 228 millions, +60% en m. l) et de la gamme Exelon (USD 209 millions, +33% en m. l) à la suite du lancement d’Exelon Patch en 2007, une formulation de patch transdermique.

Diovan (USD 2.9 billion, +6% lc) benefited from double-digit growth in Japan, which now accounts for about 20% of net sales, and a solid performance in Europe ahead of the anticipated entry of generic versions as early as the second half of 2009 of losartan, another medicine in the angiotensin receptor blockers (ARB) segment.
Diovan (USD 2,9 milliards, +6% en m. l.), a bénéficié d’une croissance à deux chiffres au Japon, qui représente actuellement quelque 20% du chiffre d’affaires net, et d’une robuste performance en Europe. On s’attend à ce que des versions génériques de losartan, un autre médicament du segment des antagonistes des récepteurs de l’angiotensine (ARA), fassent leur apparition au second semestre 2009 déjà.

Sandoz (+10% lc) benefited from the EBEWE Pharma specialty generics business acquisition in September, which added five percentage points to sales growth.
Sandoz (+10% en m. l) a bénéficié de l’acquisition du secteur d’activité des spécialités génériques d’EBEWE Pharma en septembre qui a ajouté cinq points de pourcentage à l'augmentation de son chiffre d’affaires.

Gains were also seen in the US (USD 7.1 billion, +10% lc), while Japan (USD 2.2 billion, +9% lc) benefited from new product launches.
Les Etats- Unis (USD 7,1 milliards, +10% en m. l) ont aussi affiché des gains, tandis que le Japon (USD 2,2 milliards, +9% en m. l) a bénéficié du lancement des nouveaux produits.

Cardiovascular and Metabolism (USD 2.4 billion, +10% lc) benefited from rapid expansion of the diabetes medicine Galvus (USD 66 million, +211% lc), while Novartis expanded its share of the global branded antihypertension market on gains recorded for Diovan in all key markets as well as the rollout of new single-pill combination therapies involving Tekturna/Rasilez and Exforge.
Cardiovasculaire et Métabolisme (USD 2,4 milliards, +10% en m. l) a bénéficié des progrès rapides accomplis par Galvus (USD 66 millions, +211% en m l.), un médicament contre le diabète, tandis que Novartis a accru sa part du marché mondial des marques d’hypotenseurs grâce aux gains engendrés par Diovan dans les marchés-clés ainsi que par la commercialisation de traitements combinés en un comprimé unique impliquant Rasilez/Tekturna et Exforge.

Gains were also seen in the US (USD 2.5 billion, +12% lc), while Japan (USD 889 million, +9% lc) continued to benefit from new launches in 2009.
Les Etats-Unis (USD 2,5 milliards, +12% en m. l) ont également progressé alors que le Japon (USD 889 millions, +9% en m. l) a continué de tirer profit des lancements effectués en 2009.

Table 2: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words
Table 4: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words

In concrete terms, this means that out of a hundred individuals who suffer from a mental disorder, 33 seek professional help, whereas only 27 really do receive treatment. […] The fact that between 6 and 8 out of 10 of those who suffer from a mental disorder do not receive treatment suggests that the access to mental health care is littered with stumbling blocks that have an inhibiting effect, such as the attitude towards mental health, the availability of medical care, financial considerations or the extent to which individuals think they need help”. ) (Bruffaerts et al., 2004) 14
Concrètement, cela signifie que parmi 100 personnes qui souffrent d’un trouble mental, 33 demandent une assistance professionnelle et seules 27 reçoivent effectivement un traitement.[…] Le fait que 6 à 8 personne sur 10 souffrant d’un trouble mental ne reçoivent pas de traitement indique que l’accès aux soins de santé mentale est parsemé d’embûches qui exercent un effet inhibiteur, comme l’attitude vis-à-vis de la santé mentale, l’accessibilité aux soins, des